This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Cellectar Biosciences, Inc. Identifier:
First received: January 25, 2013
Last updated: February 24, 2014
Last verified: February 2014

The purpose of this study is to determine the recommended dosing of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with glioma.

Subjects who meet study entry criteria will receive I-131-CLR1404. For each subject, the study will be conducted in three phases, dosimetric, therapy, and follow-up. In the dosimetric phase, subjects will receive one 5 mCi dose of the study drug and undergo whole body imaging on on the day of infusion and on post-infusion days 2, 3, and 7 for assessment of biodistribution and tumor uptake of I-131-CLR1404. If normal and expected biodistribution are demonstrated, the subject will begin the therapy phase. In the therapy phase, the subjects will receive a dose based on body surface area and may receive additional doses if they meet dosing criteria. After the last treatment dose, subjects will enter the follow-up phase and will be followed monthly.

All subjects will be prescribed thyroid protection medication to be taken 24 hours prior to injection of the dosimetric dose, and continuing for 14 days after the administration of the therapy dose.

Condition Intervention Phase
Glioma Drug: I-131-CLR1404 Injection Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Resource links provided by NLM:

Further study details as provided by Cellectar Biosciences, Inc.:

Primary Outcome Measures:
  • Evaluate the 6-month survival rate of subjects receiving I-131-CLR1404 for relapsed glioma [ Time Frame: 6 months ]

Enrollment: 0
Study Start Date: May 2014
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Single Group
I-131-CLR1404 Injection
Drug: I-131-CLR1404 Injection
Other Name: 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed high-grade glioblastoma multiforme (GBM)
  • Failed prior therapy with Avastin
  • Radiologic evidence of tumor progression
  • Received at least 45 Gy and no more than 66 Gy prior radiotherapy
  • Ambulatory with an ECOG performance status of 0 to 2 (Appendix C)
  • 18 years of age or older

Exclusion Criteria:

  • Received more than 25% of total bone marrow irradiated, total body or hemi-body irradiation or prior radioisotope therapy (except for benign thyroid disease)
  • Prior radiation therapy or chemotherapy within 4 weeks of start of study
  • Another active medical condition(s) or organ disease(s) that may compromise subject safety or interfere with safety and/or outcome evaluation of study drug
  • Laboratory abnormalities, including but not limited to: WBC < 3000/uL, Absolute neutrophil count < 1500/uL, Platelets < 150,000/uL, Hemoglobin ≤ 9.0 gm/dL, Total bilirubin > 1.5 x upper limit of normal for age, SGOT or SGPT > 3 x upper limit of normal for age if no liver metastases or > 5 x upper limit of normal for age in the presence of liver metastases, Serum creatinine > 1.5 x upper limit of normal for age, 2+ proteinuria or casts indicative of intrinsic renal disease
  • Treatment with investigational drug, investigational biologic, or investigational therapeutic device within 28 days of initiating study treatment
  • Received prior stem cell transplantation
  • Clinically significant cardiac co-morbidities including congestive heart failure (New York Heart Association class III-IV heart disease), left ventricular ejection fraction < 40%, unstable angina pectoris, serious cardiac arrhythmia requiring medication or pacemaker, myocardial infarction within past 6 months
  • Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters).
  • Uncontrolled hypertension as defined by systolic blood pressure > 150 mm/Hg, diastolic blood pressure > 100 mm/Hg or uncontrolled diabetes that would compromise subject safety or interfere with safety and/or outcome evaluation of study drug
  • Major surgery within 4 weeks of enrollment
  • Poor venous access and unable to receive study drug into a peripheral venous catheter
  • Significant traumatic injury within past 4 weeks
  • Ongoing or active infection requiring antibiotics or with fever >38.1º C (>101º F) within 3 days of first scheduled day of dosing
  • Receiving concurrent hemodialysis or peritoneal dialysis
  • Known positive for HIV, Hepatitis C (active, previously treated or both), or is Hepatitis B core antigen positive
  • Pregnant or lactating
  • Hospitalized
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01778088

United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Cellectar Biosciences, Inc.
Principal Investigator: Minesh Mehta, M.D., FASTRO University of Marylannd School of Medicine
  More Information

Responsible Party: Cellectar Biosciences, Inc. Identifier: NCT01778088     History of Changes
Other Study ID Numbers: DCL-13-001
Study First Received: January 25, 2013
Last Updated: February 24, 2014

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on August 16, 2017